CinDome Pharma announces successful completion of thorough QT study of CIN-102 (deudomperidone) in healthy subjects.
25. Januar 2022 08:00 ET
|
CinRx Pharma
CIN-102, Deudomperidone, is a novel, deuterium-containing, peripherally selective dopamine (D2/D3) receptor antagonist.Study demonstrated that therapeutic and ~5-fold supra-therapeutic concentrations...
CinFina Pharma In-Licenses Obesity Portfolio
22. September 2021 09:00 ET
|
CinRx Pharma
Four novel, once-weekly anorectic agents targeting significant weight lossCINCINNATI, Sept. 22, 2021 (GLOBE NEWSWIRE) -- CinFina Pharma, LLC. (“CinFina”) announced today that it has signed an...
CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102)
19. September 2019 08:30 ET
|
CinRx Pharma
CINCINNATI, Sept. 19, 2019 (GLOBE NEWSWIRE) -- CinDome Pharma, Inc. (“CinDome”), a company whose lead product is deuterated domperidone (CIN-102), today announced that is has enrolled the first...
CinRx Closes $10 Million Series B Financing
28. November 2017 08:00 ET
|
CinRx Pharma
CINCINNATI, Nov. 28, 2017 (GLOBE NEWSWIRE) -- CinRx, a biopharmaceutical company with an innovative approach to developing novel therapeutics that address diverse therapeutic areas, announced today...